These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16870552)

  • 1. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
    Litzow MR; Lee S; Bennett JM; Dewald GW; Gallagher RE; Jain V; Paietta EM; Racevskis J; Rousey SR; Mazza JJ; Tallman MS
    Haematologica; 2006 Aug; 91(8):1105-8. PubMed ID: 16870552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
    Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
    Am J Hematol; 2002 Aug; 70(4):292-9. PubMed ID: 12210810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
    Beer TM; Tangen CM; Nichols CR; Margolin KA; Dreicer R; Stephenson WT; Quinn DI; Raghavan D; Crawford ED
    Cancer; 2006 Jun; 106(12):2624-9. PubMed ID: 16688776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of arsenic trioxide in patients with metastatic melanoma.
    Kim KB; Bedikian AY; Camacho LH; Papadopoulos NE; McCullough C
    Cancer; 2005 Oct; 104(8):1687-92. PubMed ID: 16130126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
    Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
    Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
    Bajorin DF; Halabi S; Small E
    Clin Genitourin Cancer; 2009 Oct; 7(3):E66-70. PubMed ID: 19815484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
    J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
    Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
    Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
    Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
    J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lo Coco F
    Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655
    [No Abstract]   [Full Text] [Related]  

  • 12. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
    Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
    Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
    Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
    Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
    Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
    [No Abstract]   [Full Text] [Related]  

  • 17. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.
    Huguet F; Leguay T; Raffoux E; Thomas X; Beldjord K; Delabesse E; Chevallier P; Buzyn A; Delannoy A; Chalandon Y; Vernant JP; Lafage-Pochitaloff M; Chassevent A; Lhéritier V; Macintyre E; Béné MC; Ifrah N; Dombret H
    J Clin Oncol; 2009 Feb; 27(6):911-8. PubMed ID: 19124805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide.
    Au WY; Chim CS; Wai Lie AK; Pang A; Kwong YL
    Haematologica; 2002 Oct; 87(10):1109-11. PubMed ID: 12368167
    [No Abstract]   [Full Text] [Related]  

  • 19. Arsenic-induced APL differentiation in cerebrospinal fluid.
    Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
    Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.